Skip to main content
Premium Trial:

Request an Annual Quote

Caliper’s NovaScreen Division Signs Screening Deal with Wyeth

NEW YORK, June 26 (GenomeWeb News) - NovaScreen Biosciences, a Caliper Life Sciences company, will perform high-throughput screening for Wyeth Pharmaceuticals, NovaScreen said today.


Under the terms of the agreement, NovaScreen will use Caliper's LabChip 3000 microfluidic screening platform to screen 500,000 compounds against an inflammatory target.


According to NovaScreen, the LabChip 3000 technology helps eliminate false positives in the primary screen.


Financial details of the agreement were not disclosed.


Caliper purchased NovaScreen for approximately $30 million last October.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.